Based upon the accuracy of the established model for estimating OS in patients with HBV-related HCC in the early TNM stage, our study paves the way for further investigations on both RBM15 and HNRNPA2B1 as prognostic biomarkers and therapeutic targets. The gene discussed is RBM15; the disease is hepatocellular carcinoma.